JP2013536232A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013536232A5 JP2013536232A5 JP2013526060A JP2013526060A JP2013536232A5 JP 2013536232 A5 JP2013536232 A5 JP 2013536232A5 JP 2013526060 A JP2013526060 A JP 2013526060A JP 2013526060 A JP2013526060 A JP 2013526060A JP 2013536232 A5 JP2013536232 A5 JP 2013536232A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- composition
- killer
- killer cells
- cytolytic activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 40
- 239000000203 mixture Substances 0.000 claims 22
- 230000001461 cytolytic effect Effects 0.000 claims 7
- 230000002159 abnormal effect Effects 0.000 claims 6
- 102000004388 Interleukin-4 Human genes 0.000 claims 3
- 108090000978 Interleukin-4 Proteins 0.000 claims 3
- 102000001398 Granzyme Human genes 0.000 claims 2
- 108060005986 Granzyme Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000000735 allogeneic effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 210000004881 tumor cell Anatomy 0.000 claims 2
- 239000004971 Cross linker Substances 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 210000000447 Th1 cell Anatomy 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 229930192851 perforin Natural products 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40188110P | 2010-08-20 | 2010-08-20 | |
| US61/401,881 | 2010-08-20 | ||
| US201161495055P | 2011-06-09 | 2011-06-09 | |
| US61/495,055 | 2011-06-09 | ||
| PCT/US2011/048578 WO2012024666A2 (en) | 2010-08-20 | 2011-08-22 | Cells expressing th1 characteristics and cytolytic properties |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016235386A Division JP6525946B2 (ja) | 2010-08-20 | 2016-12-02 | Ｔｈ１特性と細胞溶解性を発現する細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013536232A JP2013536232A (ja) | 2013-09-19 |
| JP2013536232A5 true JP2013536232A5 (OSRAM) | 2014-10-16 |
| JP6408219B2 JP6408219B2 (ja) | 2018-10-17 |
Family
ID=45594250
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013526060A Active JP6408219B2 (ja) | 2010-08-20 | 2011-08-22 | Ｔｈ１特性と細胞溶解性を発現する細胞 |
| JP2016235386A Active JP6525946B2 (ja) | 2010-08-20 | 2016-12-02 | Ｔｈ１特性と細胞溶解性を発現する細胞 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016235386A Active JP6525946B2 (ja) | 2010-08-20 | 2016-12-02 | Ｔｈ１特性と細胞溶解性を発現する細胞 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20120045423A1 (OSRAM) |
| EP (1) | EP2606125B1 (OSRAM) |
| JP (2) | JP6408219B2 (OSRAM) |
| KR (1) | KR101900807B1 (OSRAM) |
| CN (2) | CN103068973A (OSRAM) |
| AU (1) | AU2011291477B2 (OSRAM) |
| BR (1) | BR112013003989B1 (OSRAM) |
| CA (1) | CA2808873C (OSRAM) |
| DK (1) | DK2606125T3 (OSRAM) |
| ES (1) | ES2660577T3 (OSRAM) |
| HU (1) | HUE036094T2 (OSRAM) |
| IL (1) | IL224813B (OSRAM) |
| NO (1) | NO2606125T3 (OSRAM) |
| PH (1) | PH12013500519B1 (OSRAM) |
| PL (1) | PL2606125T3 (OSRAM) |
| PT (1) | PT2606125T (OSRAM) |
| SG (2) | SG187846A1 (OSRAM) |
| TR (1) | TR201802334T4 (OSRAM) |
| WO (1) | WO2012024666A2 (OSRAM) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2808873C (en) * | 2010-08-20 | 2020-02-18 | Immunovative Therapies, Ltd. | Cells expressing th1 characteristics and cytolytic properties |
| KR101697473B1 (ko) * | 2014-11-26 | 2017-01-18 | 주식회사 녹십자랩셀 | T 세포를 이용한 자연살해세포의 배양방법 |
| CN108064176A (zh) | 2015-04-22 | 2018-05-22 | 库瑞瓦格股份公司 | 用于治疗肿瘤疾病的含有rna的组合物 |
| KR102460173B1 (ko) | 2017-05-26 | 2022-10-31 | 주식회사 지씨셀 | 형질전환된 t세포를 이용한 자연살해세포의 배양방법 |
| JP7179986B2 (ja) | 2018-11-14 | 2022-11-29 | グリーン クロス ラボ セル コーポレーション | 形質転換されたｔ細胞を用いた臍帯血由来のナチュラルキラー細胞の培養方法 |
| JP7337373B2 (ja) * | 2019-07-29 | 2023-09-04 | サイアス株式会社 | 抗原特異的ｔ細胞の製造方法 |
| US11730313B2 (en) * | 2021-02-24 | 2023-08-22 | Kirsten Wilkins | Slow cooker liner system with integrated dividers |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030050392A1 (en) * | 1998-09-22 | 2003-03-13 | Brother Kogyo Kabushiki Kaisha | Water-based ink for ink jetting and ink jet recording method |
| US20030134415A1 (en) | 2001-09-19 | 2003-07-17 | Gruenberg Micheal L. | Th1 cell adoptive immunotherapy |
| WO2003024312A2 (en) | 2001-09-17 | 2003-03-27 | Valeocyte Therapies Llc | Cell therapy system |
| US20030194395A1 (en) * | 2001-09-17 | 2003-10-16 | Gruenberg Micheal L. | Th1 cell adoptive immunotherapy |
| JP4699755B2 (ja) | 2002-08-23 | 2011-06-15 | ガブリエル ムルソフ， | 腫瘍細胞におけるアポトーシスのＨｓｐ７０／Ｈｓｐ７０ペプチド依存性誘導物質としてのグランザイムＢの使用 |
| US7402431B2 (en) | 2004-03-01 | 2008-07-22 | Immunovative Therapies, Ltd. | T-cell therapy formulation |
| US7435592B2 (en) * | 2003-05-13 | 2008-10-14 | Immunovative Therapies, Ltd. | Compositions for allogeneic cell therapy |
| DK2573166T3 (da) * | 2004-02-26 | 2016-07-04 | Immunovative Therapies Ltd | Fremgangsmåder til fremstilling af T-celler til celleterapi |
| CA2808873C (en) | 2010-08-20 | 2020-02-18 | Immunovative Therapies, Ltd. | Cells expressing th1 characteristics and cytolytic properties |
-
2011
- 2011-08-22 CA CA2808873A patent/CA2808873C/en active Active
- 2011-08-22 US US13/214,534 patent/US20120045423A1/en not_active Abandoned
- 2011-08-22 EP EP11818884.6A patent/EP2606125B1/en active Active
- 2011-08-22 DK DK11818884.6T patent/DK2606125T3/en active
- 2011-08-22 TR TR2018/02334T patent/TR201802334T4/tr unknown
- 2011-08-22 SG SG2013011069A patent/SG187846A1/en unknown
- 2011-08-22 CN CN2011800402324A patent/CN103068973A/zh active Pending
- 2011-08-22 ES ES11818884.6T patent/ES2660577T3/es active Active
- 2011-08-22 JP JP2013526060A patent/JP6408219B2/ja active Active
- 2011-08-22 PH PH1/2013/500519A patent/PH12013500519B1/en unknown
- 2011-08-22 BR BR112013003989-2A patent/BR112013003989B1/pt active IP Right Grant
- 2011-08-22 HU HUE11818884A patent/HUE036094T2/hu unknown
- 2011-08-22 PT PT118188846T patent/PT2606125T/pt unknown
- 2011-08-22 WO PCT/US2011/048578 patent/WO2012024666A2/en not_active Ceased
- 2011-08-22 CN CN201810168834.1A patent/CN108245673A/zh active Pending
- 2011-08-22 KR KR1020137004186A patent/KR101900807B1/ko active Active
- 2011-08-22 AU AU2011291477A patent/AU2011291477B2/en active Active
- 2011-08-22 SG SG10201510524TA patent/SG10201510524TA/en unknown
- 2011-08-22 NO NO11818884A patent/NO2606125T3/no unknown
- 2011-08-22 PL PL11818884T patent/PL2606125T3/pl unknown
-
2013
- 2013-02-19 IL IL224813A patent/IL224813B/en active IP Right Grant
- 2013-03-13 US US13/800,193 patent/US10385315B2/en active Active
- 2013-03-13 US US13/800,066 patent/US20130196428A1/en not_active Abandoned
-
2016
- 2016-12-02 JP JP2016235386A patent/JP6525946B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013536232A5 (OSRAM) | ||
| JP2014087372A5 (OSRAM) | ||
| Ni et al. | Sustained effector function of IL-12/15/18–preactivated NK cells against established tumors | |
| Cruz et al. | Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study | |
| Ames et al. | Advantages and clinical applications of natural killer cells in cancer immunotherapy | |
| Lang et al. | Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity | |
| JP2016539929A5 (OSRAM) | ||
| JP2015131795A5 (OSRAM) | ||
| Wang et al. | Natural killer cell awakening: Unleash cancer-immunity cycle against glioblastoma | |
| Greiner et al. | Immunological and clinical impact of manipulated and unmanipulated DLI after allogeneic stem cell transplantation of AML patients | |
| WO2014144622A3 (en) | Cd123-specific chimeric antigen receptor redirected t cells and methods of their use | |
| HK1210792A1 (en) | Molecules with antigen binding and polyvalent fc gamma receptor binding activity | |
| JP2016501013A5 (OSRAM) | ||
| JP2018522040A5 (OSRAM) | ||
| Brudno et al. | T cells expressing a novel fully-human anti-CD19 chimeric antigen receptor induce remissions of advanced lymphoma in a first-in-humans clinical trial | |
| Bachiller et al. | Natural killer cells in immunotherapy: are we nearly there? | |
| Vogler et al. | Unleashing the power of NK cells in anticancer immunotherapy | |
| Doglio et al. | Cell-based therapy in prophylaxis and treatment of chronic graft-versus-host disease | |
| Rodríguez-Agustín et al. | Immunomodulatory activity of the tyrosine kinase inhibitor dasatinib to elicit NK cytotoxicity against cancer, HIV infection and aging | |
| Beider et al. | Upregulation of senescent/exhausted phenotype of CAR T cells and induction of both treg and myeloid suppressive cells correlate with reduced response to CAR T cell therapy in relapsed/refractory B cell malignancies | |
| Delaney et al. | Cord blood graft engineering | |
| Looi et al. | Revolutionizing the treatment for nasopharyngeal cancer: the impact, challenges and strategies of stem cell and genetically engineered cell therapies | |
| JP2022023136A5 (OSRAM) | ||
| Mora-Bitria et al. | Germline natural killer cell receptors modulating the T cell response | |
| Kim et al. | Rheumatoid fibroblast-like synoviocytes downregulate Foxp3 expression by regulatory T cells Via GITRL/GITR interaction |